Early complete response of primary bone marrow B-cell lymphoma treated
with Rituximab-based CHOP therapy, assessed by flow cytometry and IGH
rearrangement
Abstract
Primary bone marrow B-cell lymphoma (PBML) is a special subtype of DLBCL
which can be repeatedly sampled and evaluated by FCM and IGH
rearrangement. Evaluation of early response by FCM and IGH assessments
in the midpoint of treatment could be valuable for predicting treatment
outcome.
